Related Experiment Videos
Prospects for the therapeutic use of anticancer vaccines
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. chamberr@mskcc.org
Abstract:
Although a century has passed since initial attempts were made to stimulate the immune system to destroy tumour, the immunotherapy of cancer is still in the early stages. Historically, a variety of specific and nonspecific immunostimulatory strategies have been administered with only modest clinical success. However, recent advances in tumour immunology, most notably the identification of genes encoding for cancer regression antigens, have paved the way for the development of a variety of novel and specific vaccine approaches. These include vaccines based on tumour cells, carbohydrates, peptides and heat-shock proteins, DNA-based vaccination, and the use of recombinant bacteria and viruses to deliver antigens or the DNA coding for them. While several of these approaches have yielded exciting clinical results, a number of immunological and host obstacles to the successful application of cancer vaccines remain. Further research is needed on the optimum choice of antigen, delivery vector, adjuvant and administration regimen.
Insights
Cancer immunotherapy, despite a century of research, is emerging. Advances in tumor immunology and novel vaccine strategies show promise, but challenges remain for effective cancer treatment.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cancer immunotherapy research began over a century ago.
- Early attempts at immunostimulation for cancer treatment yielded limited success.
- Recent progress in tumor immunology has spurred new vaccine development.
Purpose of the Study:
- To review the historical context and current advancements in cancer immunotherapy.
- To discuss novel vaccine approaches and their potential clinical applications.
- To identify remaining challenges and future research directions in cancer vaccines.
Main Methods:
- Review of historical and recent literature on cancer immunotherapy and vaccine development.
- Identification of various vaccine platforms including tumor cells, carbohydrates, peptides, heat-shock proteins, DNA, recombinant bacteria, and viruses.
- Analysis of clinical results and immunological/host obstacles.
Main Results:
- Despite historical efforts, cancer immunotherapy remains in its early stages.
- Novel vaccine strategies utilizing tumor antigens, DNA, and recombinant vectors show promising clinical results.
- Significant immunological and host-related obstacles hinder the widespread success of cancer vaccines.
Conclusions:
- Advances in identifying cancer regression antigens enable novel vaccine strategies.
- Various vaccine platforms (e.g., peptide, DNA, viral) offer potential for cancer treatment.
- Further research is crucial to overcome existing obstacles and optimize cancer vaccine efficacy.